CRISM Therapeutics (CRTX) Competitors GBX 11 +0.25 (+2.33%) As of 08/8/2025 11:18 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock CRTX vs. ATN, AYM, BEM, ORM, FRG, PFP, PYX, AFP, REE, and THRShould you be buying CRISM Therapeutics stock or one of its competitors? The main competitors of CRISM Therapeutics include Aterian (ATN), Anglesey Mining (AYM), Beowulf Mining (BEM), Ormonde Mining (ORM), Firering Strategic Minerals (FRG), Pathfinder Minerals (PFP), PYX Resources (PYX), African Pioneer (AFP), Altona Rare Earths (REE), and Thor Energy (THR). These companies are all part of the "other industrial metals & mining" industry. CRISM Therapeutics vs. Its Competitors Aterian Anglesey Mining Beowulf Mining Ormonde Mining Firering Strategic Minerals Pathfinder Minerals PYX Resources African Pioneer Altona Rare Earths Thor Energy Aterian (LON:ATN) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment. Does the media favor ATN or CRTX? In the previous week, Aterian's average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score. Company Overall Sentiment Aterian Neutral CRISM Therapeutics Neutral Which has better valuation and earnings, ATN or CRTX? Aterian is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAterianN/AN/A-£2.26K-£0.02-1,867.71CRISM TherapeuticsN/AN/A-£792.20K-£5.81-1.89 Is ATN or CRTX more profitable? Aterian's return on equity of -5.93% beat CRISM Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AterianN/A -5.93% -14.49% CRISM Therapeutics N/A -13.12%-26.77% Do insiders and institutionals believe in ATN or CRTX? 12.4% of Aterian shares are owned by institutional investors. 70.1% of Aterian shares are owned by company insiders. Comparatively, 68.8% of CRISM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, ATN or CRTX? Aterian has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Comparatively, CRISM Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. SummaryAterian beats CRISM Therapeutics on 6 of the 8 factors compared between the two stocks. Get CRISM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON ExchangeMarket Cap£1.20M£1.06B£3.30B£3.07BDividend YieldN/A6.19%5.18%5.03%P/E Ratio-1.89127.06109.95170.60Price / SalesN/A22,836.5531,270,591,557,371,800.00303,757.13Price / CashN/A24.7023.9627.96Price / Book0.267.236.014.52Net Income-£792.20K£71.98M£148.72M£5.90B7 Day Performance4.07%5.27%3.90%1.24%1 Month Performance-5.74%7.80%4.15%3.63%1 Year PerformanceN/A47.84%37.31%58.43% CRISM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCRISM TherapeuticsN/AGBX 11+2.3%N/AN/A£1.20MN/A-1.894ATNAterianN/AGBX 34.50flatN/A-38.6%£4.15MN/A-1,841.0322AYMAnglesey MiningN/AGBX 0.80+3.2%N/A-17.2%£4.08MN/A-0.012BEMBeowulf MiningN/AGBX 10.01-4.7%N/A-57.7%£3.89MN/A-2.0513Gap DownORMOrmonde MiningN/AN/AN/AN/A£3.54MN/A-2.506FRGFirering Strategic MineralsN/AGBX 1.60+8.5%N/A-46.8%£3.53MN/A-1.37N/APFPPathfinder MineralsN/AN/AN/AN/A£2.92MN/A-5.255PYXPYX ResourcesN/AGBX 0.56-10.5%N/A-92.1%£2.60M£21.97M-1.2895Gap UpAFPAfrican PioneerN/AGBX 1.05+4.8%N/A-57.0%£2.40M£34.91K-3.375Gap UpREEAltona Rare EarthsN/AGBX 1.44-7.0%N/A-16.2%£2.35MN/A-48.07270Gap DownTHRThor EnergyN/AGBX 0.49+3.2%N/A-39.4%£2.34MN/A-0.701,083Gap Up Related Companies and Tools Related Companies Aterian Alternatives Anglesey Mining Alternatives Beowulf Mining Alternatives Ormonde Mining Alternatives Firering Strategic Minerals Alternatives Pathfinder Minerals Alternatives PYX Resources Alternatives African Pioneer Alternatives Altona Rare Earths Alternatives Thor Energy Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:CRTX) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISM Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
